CN103989170A - Solid granules capable of reducing blood fat and relaxing bowels and preparation method of solid granules - Google Patents
Solid granules capable of reducing blood fat and relaxing bowels and preparation method of solid granules Download PDFInfo
- Publication number
- CN103989170A CN103989170A CN201410223494.XA CN201410223494A CN103989170A CN 103989170 A CN103989170 A CN 103989170A CN 201410223494 A CN201410223494 A CN 201410223494A CN 103989170 A CN103989170 A CN 103989170A
- Authority
- CN
- China
- Prior art keywords
- fermentation
- time
- sterilizing
- solid granules
- liquid nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 28
- 239000007787 solid Substances 0.000 title claims abstract description 28
- 210000004369 blood Anatomy 0.000 title claims abstract description 23
- 239000008280 blood Substances 0.000 title claims abstract description 23
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 238000000855 fermentation Methods 0.000 claims abstract description 62
- 230000004151 fermentation Effects 0.000 claims abstract description 62
- 239000007788 liquid Substances 0.000 claims abstract description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 25
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 15
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 14
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 14
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 14
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- 235000004426 flaxseed Nutrition 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 235000013336 milk Nutrition 0.000 claims abstract description 13
- 239000008267 milk Substances 0.000 claims abstract description 13
- 210000004080 milk Anatomy 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 13
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 48
- 230000001954 sterilising effect Effects 0.000 claims description 36
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 28
- 244000068988 Glycine max Species 0.000 claims description 25
- 235000010469 Glycine max Nutrition 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 18
- 235000014655 lactic acid Nutrition 0.000 claims description 14
- 239000004310 lactic acid Substances 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 235000013557 nattō Nutrition 0.000 claims description 13
- 244000298479 Cichorium intybus Species 0.000 claims description 12
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 12
- 240000006240 Linum usitatissimum Species 0.000 claims description 12
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 12
- 244000057214 Stachys sieboldii Species 0.000 claims description 12
- 235000005116 Stachys sieboldii Nutrition 0.000 claims description 12
- 239000000919 ceramic Substances 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 12
- 238000001125 extrusion Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- 239000002131 composite material Substances 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 238000001471 micro-filtration Methods 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 24
- 235000012000 cholesterol Nutrition 0.000 abstract description 11
- 206010010774 Constipation Diseases 0.000 abstract description 8
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 abstract description 2
- 230000029142 excretion Effects 0.000 abstract description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 244000063299 Bacillus subtilis Species 0.000 abstract 1
- 235000014469 Bacillus subtilis Nutrition 0.000 abstract 1
- 206010007191 Capillary fragility Diseases 0.000 abstract 1
- 240000006740 Cichorium endivia Species 0.000 abstract 1
- 244000019459 Cynara cardunculus Species 0.000 abstract 1
- 235000019106 Cynara scolymus Nutrition 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 241000266501 Ormosia ormondii Species 0.000 abstract 1
- 241001247821 Ziziphus Species 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 235000016520 artichoke thistle Nutrition 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 235000003733 chicria Nutrition 0.000 abstract 1
- 238000000227 grinding Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940086319 nattokinase Drugs 0.000 description 2
- 108010073682 nattokinase Proteins 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000036471 Melanosis coli Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses solid granules capable of lowering blood fat and relaxing bowels and a preparation method of the solid granules. The preparation method comprises the following steps: grinding yellow beans, expanding, adding glucose, NaCl, dried orange peel, red jujubes, artichoke, endives, flaxseeds, bacillus natto, bacillus lacticus, lactobacillus plantarum, lactobacillus rhamnosus and milk powder, performing liquid fermentation twice, concentrating and drying. The solid granules are capable of dissolving thrombi caused by platelet aggregation, reducing lipid thrombi and blood viscosity caused by cholesterol crystal and lipid plaque adhesion, improving blood circulation and intestinal microecological environment and effectively preventing and treating gastrointestinal diseases such as constipation. Meanwhile, the solid granules are also capable of promoting cholesterol excretion, inhibiting endogenous cholesterol synthesis, reducing the content of triglyceride, low-density lipoprotein and very-low-density lipoprotein and increasing the content of high-density serum lipoprotein so as to improve serum lipid, reduce capillary fragility caused by hyperlipidemia and arteriosclerosis, and protect heart and cerebral vessels.
Description
Technical field
The present invention relates to a kind of health food electuary and preparation method thereof, specifically a kind of solid granules can reducing blood lipid relaxing bowel and preparation method thereof, belongs to food engineering field.
Background technology
Along with the quickening of people's rhythm of life and improving constantly of food fine finishining degree, the balance of diet structure is difficult to keep, cause the continuous expansion of people with hyperlipidemia, the strict difinition of high fat of blood should be blood fat disorder or dyslipidemia, the concentration level that refers to blood in human body in fat eliminating matter has exceeded normal range (NR), comprise that serum total cholesterol (TC) level raises, serum levels of triglyceride (TG) level raises, and serum High Density Lipoprotein Cholesterol (HDL-C) level reduces.High fat of blood is very harmful to human body, medical research shows, high fat of blood is the most important pathogenesis of angiocardiopathy such as ischemic myocardial infarct, coronary heart disease and apoplexy, and the main cause that blood fat raises is to be caused by bad dietary factor, habits and customs and inherent cause etc.Meanwhile, intestinal beneficial bacterium reduces the final synthetic and absorption that also can cause cholesterol and increases, and aggravates hyperlipemia.China's dyslipidemia number has exceeded 100,000,000 at present according to statistics.Treatment high fat of blood is mainly to treat and two kinds of approach of non-drug therapy by medicine, the most frequently used lipid-regulation medicine has two large classes, Statins is mainly that the rate-limiting enzyme reductase by resisting cholesterol biosynthesis reduces LDL-C level, the special class of shellfish is mainly to increase lipoprotein lipase activity, adding VLDL decomposes, it is easily to produce drug dependence that medicine is adjusted the defect of fat, and long-term taking there will be the bad reactions such as hepatorenal damage, rhabdomyolysis, stomachache, fash, and cure the symptoms, not the disease, very easily recurrence after drug withdrawal.
Intestinal microecology system, as a part for normal enteron aisle structure, plays a very important role the normal performance of function of intestinal canal.But because modern is subject to many-sided impacts the such as quickening, the psychology and society factor of change, the rhythm of life of dietary structure, the use of broad-spectrum antibiotic, there is intestinal bacilli illness and made the pathogenic phenomenon of host, as disease of digestive systems such as acute and chronic diarrhea, constipation, IBS, inflammatory enteritis, and the metabolism related diseases such as Dyslipidemia, chronic constipation and cardiovascular and cerebrovascular diseases, colon cancer and senile dementia etc. occur relevant, are having a strong impact on people's quality of life.Preventing and treating at present chronic functional constipation is main mainly with medicine treatment, but the use of cathartic can cause abdominal distension, liposoluble vitamin malabsorption, melanosis coli, electrolyte wadding disorderly, headache, the side effect such as feel sick.Research discovery, constipation person's faecal microbiota changes, and Bifidobacterium and bacteroid number reduce, and especially clostridium reduces.
And probiotics is having certain using value aspect the treatment of the gastroenteritic power diseases such as chronic constipation and high fat of blood.Therefore develop and a kind ofly there is blood fat reducing function, and can be by improving intestine microenvironment pursue the demand of healthy Green Lifestyle in case the health food of the not only nutrition treating constipation but also instant edible meets Modern human populations.
Summary of the invention
The object of the invention is for hypolipidemic in the market and cathartic kind is single, side effect is large defect, and a kind of solid granules can reducing blood lipid relaxing bowel and preparation method thereof is disclosed, this electuary can reduce blood fat, can reach the effect relaxing bowel by improving gut flora micro-ecological environment again.
Solid granules of the present invention is composite by the raw material of following component and weight portion:
Soya bean 10 ~ 45, glucose 0.4 ~ 3, NaCl 0.05 ~ 0.1, dried orange peel 3 ~ 10, enuleation date 2 ~ 15, Chinese artichoke 5 ~ 20, witloof 4 ~ 15, linseed 10 ~ 35, bafillus natto 1 ~ 5.5, lactic acid bacillus 0.5 ~ 3, Lactobacillus plantarum 0.5 ~ 3, Lactobacillus rhamnosus 0.7 ~ 3.3, milk powder 0.5 ~ 1.5, water 80 ~ 360.
Solid granules of the present invention is to have prepared by following steps:
A. pulverize and extrusion
A.1 soya bean is pulverized, adjusts water content 14% ~ 19%,
A.2 then carry out extrusion, screw rod rotating speed 80r/min ~ 160r/min, rate of feeding
30g/min ~ 150g/min, 135 ~ 140 DEG C of temperature,
A.3 again pulverize with pulverizer, cross 80 mesh sieves and become analysis for soybean powder; Pulverizer rotating speed 10000r/min,
Time 4 ~ 10min;
B. a liquid state fermentation
B.1 analysis for soybean powder, glucose, NaCl and water are added by weight to sterilizing in the lump in fermentation tank, 121 ~ 126 DEG C of sterilising temps, time 30 ~ 35min,
B.2 then bafillus natto is inoculated by weight to fermentation cylinder for fermentation after sterilizing and cultivated, 34 ~ 37 DEG C of fermented and cultured temperature, initial pH are 7 ~ 8, speed of agitator 120 ~ 140r/min, fermentating liquid volume and the volume ratio that passes into air per minute are 1:0.4 ~ 0.6, time 28 ~ 30h;
C. secondary liquid fermentation
C.1 dried orange peel, enuleation date, Chinese artichoke, witloof, linseed are mixed by corresponding weight portion, are then dried, low temperature liquid nitrogen is pulverized, add in fermentation tank after sterilizing,
C.1.1 60 ~ 80 DEG C of baking temperatures, time 1.5 ~ 3h,
C.1.2 to pulverize voltage 220V, speed of mainshaft 2500r/min, power of motor 1500W, 10 DEG C ~-20 DEG C of temperature, spray amount of liquid nitrogen be 0.05 ~ 1kg liquid nitrogen/kg raw material to low temperature liquid nitrogen,
C.1.3 121 ~ 135 DEG C of sterilising temps, time 10 ~ 20min;
C.2 add in the lump fermentation cylinder for fermentation to cultivate by corresponding weight portion the milk powder after lactic acid bacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, sterilizing,
C.2.1 30 ~ 37 DEG C of fermented and cultured temperature, initial pH value 6 ~ 7,
C.2.2 fermentation initially stops ventilating, and stirs 5min, fermented incubation time 48 ~ 52h every 1 ~ 2h;
D. concentrate and be dried
D.1 zymotic fluid is concentrated to inorganic ceramic membrane pore footpath 0.2 μ m, concentrated pressure 0.15 ~ 0.18MPa, membrane area 0.25m with inorganic ceramic membrane pipe micro-filtration
2,
D.2 concentrate is drying to obtain to solid granules through low temperature fluid bed, 40 ~ 60 DEG C of dry EATs, wind speed are 1.8 ~ 2.2 m/s, time 40 ~ 70min.
The present invention adopts the mode of twice liquid state fermentation to prepare solid granules, makes final fermented prod contain the multiple active ingredient with reducing blood lipid and regulating intestinal canal colony balance.Liquid state fermentation is for the first time aerobic fermentation, make bafillus natto raised growth and produce Nattokinase, the lactic acid bacillus of the inoculation of liquid state fermentation is for the second time facultative anaerobe, after stopping ventilating, remaining oxygen in fermentation tank can be used up, giving latter two bacterium is the growing environment that Lactobacillus plantarum and Lactobacillus rhamnosus have been created anaerobic, three kinds of bacterium produce a series of enzyme and are, make the thick dimension element in fermentation raw material, the mass degradation such as high molecular weight protein and carbohydrate, in addition, lactic acid bacillus also can produce some special enzyme systems, such as the enzyme system of synthetic polysaccharide, reduce the enzyme system of cholesterol, the enzyme system of synthesise various vitamins, the generation of these enzyme systems can not only be accelerated the growth of thalline, maintain intestinal microecology balance, can also make the nutritional labeling utilization rate in raw material increase, improve some as rutin, vitamin C, the content of the functional components such as dried orange peel glycosides, can also improve the bad flavor that liquid state fermentation soya bean produces for the first time simultaneously.The fermentation initial stage gives probio the preferential carbon source of utilizing by adding a certain amount of lactose, has avoided the prebiotics adding to be utilized too much.
Solid granules prepared by the present invention not only can dissolve the thrombus being caused by platelet aggregation, can also reduce by cholesterol crystal and Lipid Plaque and adhere to the lipid thrombus causing, reduce blood viscosity, improve blood circulation, softening and increase blood vessel elasticity, improve the permeability of blood vessel; Secondly can increase Cholesterol Excretion; and it is synthetic to suppress endogenous cholesterol; reduce triglycerides, low-density lipoprotein and extra-low density albumen; rising serum high-density LP; improve serum lipids thereby reach; the fragility of blood vessels that reduction high fat of blood, artery sclerosis cause, to protect cardiovascular and cerebrovascular.Take in the four kinds of probios and the corresponding prebiotics that in electuary, contain and not only can improve intestine microenvironment, the effectively anti-enterogastric diseases such as treat constipation, thereby the probio of propagation can also have obvious mitigation to high fat of blood by suppressing the synthetic of cholesterol, avoid because of the antibody-resistant bacterium that the abuse of antibiotic etc causes, the problem such as diffusion and drug dependence of drug-resistance factor, application is wide, and security is higher.
Detailed description of the invention
Now provide following two embodiment, but the present invention is not limited to following examples:
Embodiment 1: solid granules of the present invention is composite by the raw material of following component and weight portion:
Soya bean 10 ~ 20, glucose 0.4 ~ 1.7, NaCl 0.05 ~ 0.07, dried orange peel 3 ~ 6, enuleation date 7 ~ 15, Chinese artichoke 5 ~ 10, witloof 4 ~ 8, linseed 10 ~ 23, bafillus natto 1 ~ 3, lactic acid bacillus 0.5 ~ 2.5, Lactobacillus plantarum 0.5 ~ 2, Lactobacillus rhamnosus 0.7 ~ 2.4, milk powder 0.5 ~ 1, water 80 ~ 160.
Solid granules of the present invention is to have prepared by following steps:
A. pulverize and extrusion
A.1 soya bean is pulverized, adjusts water content 15% ~ 17%,
A.2 then carry out extrusion, screw rod rotating speed 130r/min, rate of feeding 90g/min, temperature
Spend 135 DEG C,
A.3 again pulverize with pulverizer, cross 80 mesh sieves and become analysis for soybean powder; Pulverizer rotating speed 10000r/min,
Time 4min;
B. a liquid state fermentation
B.1 analysis for soybean powder, glucose, NaCl and water are added by weight to sterilizing in the lump in fermentation tank, 121 DEG C of sterilising temps, time 35min,
B.2 then bafillus natto is inoculated by weight to fermentation cylinder for fermentation after sterilizing and cultivated, 35 DEG C of fermented and cultured temperature, initial pH are 7, speed of agitator 120r/min, fermentating liquid volume and the volume ratio that passes into air per minute are 1:0.4, time 28h;
C. secondary liquid fermentation
C.1 dried orange peel, enuleation date, Chinese artichoke, witloof, linseed are mixed by corresponding weight portion, are then dried, low temperature liquid nitrogen is pulverized, add in fermentation tank after sterilizing,
C.1.1 70 DEG C of baking temperatures, time 2h,
C.1.2 low temperature liquid nitrogen is pulverized 0 DEG C of voltage 220V, speed of mainshaft 2500r/min, power of motor 1500W, temperature, and spraying amount of liquid nitrogen is 0.06kg liquid nitrogen/kg raw material,
C.1.3 121 DEG C of sterilising temps, time 20min;
C.2 add in the lump fermentation cylinder for fermentation to cultivate by corresponding weight portion the milk powder after lactic acid bacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, sterilizing,
C.2.1 32 DEG C of fermented and cultured temperature, initial pH value 7,
C.2.2 fermentation initially stops ventilating, and stirs 5min, fermented incubation time 48h every 1.5h;
D. concentrate and be dried
D.1 zymotic fluid is concentrated to inorganic ceramic membrane pore footpath 0.2 μ m, concentrated pressure 0.15MPa, membrane area 0.25m with inorganic ceramic membrane pipe micro-filtration
2,
D.2 concentrate is drying to obtain to solid granules through low temperature fluid bed, 40 DEG C of dry EATs, wind speed 1.9 m/s, time 50min.
Embodiment 2: solid granules of the present invention is composite by the raw material of following component and weight portion:
Soya bean 18 ~ 40, glucose 0.6 ~ 2, NaCl 0.06 ~ 0.09, dried orange peel 5 ~ 10, enuleation date 6 ~ 14, Chinese artichoke 8 ~ 15, witloof 7 ~ 15, linseed 17 ~ 30, bafillus natto 2 ~ 4, lactic acid bacillus 1 ~ 2.5, Lactobacillus plantarum 1.5 ~ 2.5,1.5 ~ 3 parts of Lactobacillus rhamnosus, milk powder 0.7 ~ 1.1, water 144 ~ 320.
Solid granules of the present invention is to have prepared by following steps:
A. pulverize and extrusion
A.1 soya bean is pulverized, adjusts water content 17% ~ 19%,
A.2 then carry out extrusion, screw rod rotating speed 135r/min, rate of feeding 80g/min, temperature
Spend 140 DEG C,
A.3 again pulverize with pulverizer, cross 80 mesh sieves and become analysis for soybean powder; Pulverizer rotating speed 10000r/min,
Time 5min;
B. a liquid state fermentation
B.1 analysis for soybean powder, glucose, NaCl and water are added by weight to sterilizing in the lump in fermentation tank, 125 DEG C of sterilising temps, time 30min,
B.2 then bafillus natto is inoculated by weight to fermentation cylinder for fermentation after sterilizing and cultivated, 37 DEG C of fermented and cultured temperature, initial pH are 8, speed of agitator 130r/min, fermentating liquid volume and the volume ratio that passes into air per minute are 1:0.5, time 30h;
C. secondary liquid fermentation
C.1 dried orange peel, enuleation date, Chinese artichoke, witloof, linseed are mixed by corresponding weight portion, are then dried, low temperature liquid nitrogen is pulverized, add in fermentation tank after sterilizing,
C.1.1 70 DEG C of baking temperatures, time 2h,
C.1.2 low temperature liquid nitrogen pulverize voltage 220V, speed of mainshaft 2500r/min, power of motor 1500W, temperature for-10 DEG C, to spray amount of liquid nitrogen be 0.09kg liquid nitrogen/kg raw material,
C.1.3 135 DEG C of sterilising temps, time 10min;
C.2 add in the lump fermentation cylinder for fermentation to cultivate by corresponding weight portion the milk powder after lactic acid bacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, sterilizing,
C.2.1 34 DEG C of fermented and cultured temperature, initial pH value 7,
C.2.2 fermentation initially stops ventilating, and stirs 5min, fermented incubation time 50h every 1h;
D. concentrate and be dried
D.1 zymotic fluid is concentrated to inorganic ceramic membrane pore footpath 0.2 μ m, concentrated pressure 0.17MPa, membrane area 0.25m with inorganic ceramic membrane pipe micro-filtration
2,
D.2 concentrate is drying to obtain to solid granules through low temperature fluid bed, 55 DEG C of dry EATs, wind speed 1.8 m/s, time 60min.
The eating method of solid granules of the present invention: because of Nattokinase rapid deactivation in the time that temperature exceedes 70 DEG C, suggestion brews and drinks by cold water or warm water (<50 DEG C).
Claims (3)
1. the solid granules can reducing blood lipid relaxing bowel, is characterized in that by the raw material of following component and weight portion composite: soya bean 10 ~ 45, glucose 0.4 ~ 3, NaCl 0.05 ~ 0.1, dried orange peel 3 ~ 10, enuleation date 2 ~ 15, Chinese artichoke 5 ~ 20, witloof 4 ~ 15, linseed 10 ~ 35, bafillus natto 1 ~ 5.5, lactic acid bacillus 0.5 ~ 3, Lactobacillus plantarum 0.5 ~ 3, Lactobacillus rhamnosus 0.7 ~ 3.3, milk powder 0.5 ~ 1.5, water 80 ~ 360;
Described solid granules is to have prepared by following steps:
A. pulverize and extrusion
A.1 soya bean is pulverized, adjusts water content 14% ~ 19%,
A.2 then carry out extrusion, screw rod rotating speed 80r/min ~ 160r/min, rate of feeding
30g/min ~ 150g/min, 135 ~ 140 DEG C of temperature,
A.3 again pulverize with pulverizer, cross 80 mesh sieves and become analysis for soybean powder; Pulverizer rotating speed 10000r/min,
Time 4 ~ 10min;
B. a liquid state fermentation
B.1 analysis for soybean powder, glucose, NaCl and water are added by weight to sterilizing in the lump in fermentation tank, 121 ~ 126 DEG C of sterilising temps, time 30 ~ 35min,
B.2 then bafillus natto is inoculated by weight to fermentation cylinder for fermentation after sterilizing and cultivated, 34 ~ 37 DEG C of fermented and cultured temperature, initial pH are 7 ~ 8, speed of agitator 120 ~ 140r/min, fermentating liquid volume and the volume ratio that passes into air per minute are 1:0.4 ~ 0.6, time 28 ~ 30h;
C. secondary liquid fermentation
C.1 dried orange peel, enuleation date, Chinese artichoke, witloof, linseed are mixed by corresponding weight portion, are then dried, low temperature liquid nitrogen is pulverized, add in fermentation tank after sterilizing,
C.1.1 60 ~ 80 DEG C of baking temperatures, time 1.5 ~ 3h,
C.1.2 to pulverize voltage 220V, speed of mainshaft 2500r/min, power of motor 1500W, 10 DEG C ~-20 DEG C of temperature, spray amount of liquid nitrogen be 0.05 ~ 1kg liquid nitrogen/kg raw material to low temperature liquid nitrogen,
C.1.3 121 ~ 135 DEG C of sterilising temps, time 10 ~ 20min;
C.2 add in the lump fermentation cylinder for fermentation to cultivate by corresponding weight portion the milk powder after lactic acid bacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, sterilizing,
C.2.1 30 ~ 37 DEG C of fermented and cultured temperature, initial pH value 6 ~ 7,
C.2.2 fermentation initially stops ventilating, and stirs 5min, fermented incubation time 48 ~ 52h every 1 ~ 2h;
D. concentrate and be dried
D.1 zymotic fluid is concentrated to inorganic ceramic membrane pore footpath 0.2 μ m, concentrated pressure 0.15 ~ 0.18MPa, membrane area 0.25m with inorganic ceramic membrane pipe micro-filtration
2,
D.2 concentrate is drying to obtain to solid granules through low temperature fluid bed, 40 ~ 60 DEG C of dry EATs, wind speed are 1.8 ~ 2.2 m/s, time 40 ~ 70min.
2. the solid granules can reducing blood lipid relaxing bowel according to claim 1, is characterized in that by the raw material of following component and weight portion composite: soya bean 10 ~ 20, glucose 0.4 ~ 1.7, NaCl 0.05 ~ 0.07, dried orange peel 3 ~ 6, enuleation date 7 ~ 15, Chinese artichoke 5 ~ 10, witloof 4 ~ 8, linseed 10 ~ 23, bafillus natto 1 ~ 3, lactic acid bacillus 0.5 ~ 2.5, Lactobacillus plantarum 0.5 ~ 2, Lactobacillus rhamnosus 0.7 ~ 2.4, milk powder 0.5 ~ 1, water 80 ~ 160;
And prepare by following steps:
A. pulverize and extrusion
A.1 soya bean is pulverized, adjusts water content 15% ~ 17%,
A.2 then carry out extrusion, screw rod rotating speed 130r/min, rate of feeding 90g/min,
135 DEG C of temperature,
A.3 again pulverize with pulverizer, cross 80 mesh sieves and become analysis for soybean powder; Pulverizer rotating speed 10000r/min,
Time 4min;
B. a liquid state fermentation
B.1 analysis for soybean powder, glucose, NaCl and water are added by weight to sterilizing in the lump in fermentation tank, 121 DEG C of sterilising temps, time 35min,
B.2 then bafillus natto is inoculated by weight to fermentation cylinder for fermentation after sterilizing and cultivated, 35 DEG C of fermented and cultured temperature, initial pH are 7, speed of agitator 120r/min, fermentating liquid volume and the volume ratio that passes into air per minute are 1:0.4, time 28h;
C. secondary liquid fermentation
C.1 dried orange peel, enuleation date, Chinese artichoke, witloof, linseed are mixed by corresponding weight portion, are then dried, low temperature liquid nitrogen is pulverized, add in fermentation tank after sterilizing,
C.1.1 70 DEG C of baking temperatures, time 2h,
C.1.2 low temperature liquid nitrogen is pulverized 0 DEG C of voltage 220V, speed of mainshaft 2500r/min, power of motor 1500W, temperature, and spraying amount of liquid nitrogen is 0.06kg liquid nitrogen/kg raw material,
C.1.3 121 DEG C of sterilising temps, time 20min;
C.2 add in the lump fermentation cylinder for fermentation to cultivate by corresponding weight portion the milk powder after lactic acid bacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, sterilizing,
C.2.1 32 DEG C of fermented and cultured temperature, initial pH value 7,
C.2.2 fermentation initially stops ventilating, and stirs 5min, fermented incubation time 48h every 1.5h;
D. concentrate and be dried
D.1 zymotic fluid is concentrated to inorganic ceramic membrane pore footpath 0.2 μ m, concentrated pressure 0.15MPa, membrane area 0.25m with inorganic ceramic membrane pipe micro-filtration
2,
D.2 concentrate is drying to obtain to solid granules through low temperature fluid bed, 40 DEG C of dry EATs, wind speed 1.9 m/s, time 50min.
3. the solid granules can reducing blood lipid relaxing bowel according to claim 1, is characterized in that by the raw material of following component and weight portion composite: soya bean 18 ~ 40, glucose 0.6 ~ 2, NaCl 0.06 ~ 0.09, dried orange peel 5 ~ 10, enuleation date 6 ~ 14, Chinese artichoke 8 ~ 15, witloof 7 ~ 15, linseed 17 ~ 30, bafillus natto 2 ~ 4, lactic acid bacillus 1 ~ 2.5, Lactobacillus plantarum 1.5 ~ 2.5,1.5 ~ 3 parts of Lactobacillus rhamnosus, milk powder 0.7 ~ 1.1, water 144 ~ 320;
And prepare by following steps:
A. pulverize and extrusion
A.1 soya bean is pulverized, adjusts water content 17% ~ 19%,
A.2 then carry out extrusion, screw rod rotating speed 135r/min, rate of feeding 80g/min,
140 DEG C of temperature,
A.3 again pulverize with pulverizer, cross 80 mesh sieves and become analysis for soybean powder; Pulverizer rotating speed 10000r/min,
Time 5min;
B. a liquid state fermentation
B.1 analysis for soybean powder, glucose, NaCl and water are added by weight to sterilizing in the lump in fermentation tank, 125 DEG C of sterilising temps, time 30min,
B.2 then bafillus natto is inoculated by weight to fermentation cylinder for fermentation after sterilizing and cultivated, 37 DEG C of fermented and cultured temperature, initial pH are 8, speed of agitator 130r/min, fermentating liquid volume and the volume ratio that passes into air per minute are 1:0.5, time 30h;
C. secondary liquid fermentation
C.1 dried orange peel, enuleation date, Chinese artichoke, witloof, linseed are mixed by corresponding weight portion, are then dried, low temperature liquid nitrogen is pulverized, add in fermentation tank after sterilizing,
C.1.1 70 DEG C of baking temperatures, time 2h,
C.1.2 low temperature liquid nitrogen pulverize voltage 220V, speed of mainshaft 2500r/min, power of motor 1500W, temperature for-10 DEG C, to spray amount of liquid nitrogen be 0.09kg liquid nitrogen/kg raw material,
C.1.3 135 DEG C of sterilising temps, time 10min;
C.2 add in the lump fermentation cylinder for fermentation to cultivate by corresponding weight portion the milk powder after lactic acid bacillus, Lactobacillus plantarum, Lactobacillus rhamnosus, sterilizing,
C.2.1 34 DEG C of fermented and cultured temperature, initial pH value 7,
C.2.2 fermentation initially stops ventilating, and stirs 5min, fermented incubation time 50h every 1h;
D. concentrate and be dried
D.1 zymotic fluid is concentrated to inorganic ceramic membrane pore footpath 0.2 μ m, concentrated pressure 0.17MPa, membrane area 0.25m with inorganic ceramic membrane pipe micro-filtration
2,
D.2 concentrate is drying to obtain to solid granules through low temperature fluid bed, 55 DEG C of dry EATs, wind speed 1.8 m/s, time 60min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410223494.XA CN103989170B (en) | 2014-05-26 | 2014-05-26 | Solid granules capable of reducing blood fat and relaxing bowels and preparation method of solid granules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410223494.XA CN103989170B (en) | 2014-05-26 | 2014-05-26 | Solid granules capable of reducing blood fat and relaxing bowels and preparation method of solid granules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103989170A true CN103989170A (en) | 2014-08-20 |
| CN103989170B CN103989170B (en) | 2015-06-10 |
Family
ID=51303710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410223494.XA Active CN103989170B (en) | 2014-05-26 | 2014-05-26 | Solid granules capable of reducing blood fat and relaxing bowels and preparation method of solid granules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103989170B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104146272A (en) * | 2014-08-28 | 2014-11-19 | 安徽燕之坊食品有限公司 | High-protein complementing medicinal granule and preparation method thereof |
| CN104305189A (en) * | 2014-10-16 | 2015-01-28 | 山东天康生物科技股份有限公司 | Blood fat reducing and bowel relaxing liquid preparation and preparation method thereof |
| CN109251877A (en) * | 2018-10-13 | 2019-01-22 | 北京首佳利华科技有限公司 | It is a kind of with the bafillus natto Bn-SJLH001 prebiotic effect of the functions such as fat reducing and its application |
| CN109331045A (en) * | 2018-11-23 | 2019-02-15 | 福建省微生物研究所 | It is a kind of containing Bee Pollen, the probiotic composition of active carbon and preparation method thereof |
| KR102468230B1 (en) * | 2022-08-19 | 2022-11-18 | 주식회사 레이어스코스메틱 | A fermentation method of raw material using lactobacillus strain |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019678A (en) * | 2007-02-16 | 2007-08-22 | 罗权浩 | Health preserving solid beverage |
| CN103098873A (en) * | 2012-12-11 | 2013-05-15 | 苏启飞 | Peanut and red date sour milk beverage |
| CN103385315A (en) * | 2013-08-06 | 2013-11-13 | 南京弘典医药科技有限公司 | Vegetable oil composition with hypolipidemic effect as well as preparation method and application thereof |
| CN103431318A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for female color-spot patients |
| CN103431376A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for constipation patients |
-
2014
- 2014-05-26 CN CN201410223494.XA patent/CN103989170B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019678A (en) * | 2007-02-16 | 2007-08-22 | 罗权浩 | Health preserving solid beverage |
| CN103098873A (en) * | 2012-12-11 | 2013-05-15 | 苏启飞 | Peanut and red date sour milk beverage |
| CN103431318A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for female color-spot patients |
| CN103431376A (en) * | 2013-07-18 | 2013-12-11 | 浙江劲膳美生物科技有限公司 | Special diet edible for constipation patients |
| CN103385315A (en) * | 2013-08-06 | 2013-11-13 | 南京弘典医药科技有限公司 | Vegetable oil composition with hypolipidemic effect as well as preparation method and application thereof |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104146272A (en) * | 2014-08-28 | 2014-11-19 | 安徽燕之坊食品有限公司 | High-protein complementing medicinal granule and preparation method thereof |
| CN104305189A (en) * | 2014-10-16 | 2015-01-28 | 山东天康生物科技股份有限公司 | Blood fat reducing and bowel relaxing liquid preparation and preparation method thereof |
| CN109251877A (en) * | 2018-10-13 | 2019-01-22 | 北京首佳利华科技有限公司 | It is a kind of with the bafillus natto Bn-SJLH001 prebiotic effect of the functions such as fat reducing and its application |
| CN109251877B (en) * | 2018-10-13 | 2020-11-03 | 北京首佳利华科技有限公司 | Bacillus natto Bn-SJLH001 with fat reducing function and application thereof |
| CN109331045A (en) * | 2018-11-23 | 2019-02-15 | 福建省微生物研究所 | It is a kind of containing Bee Pollen, the probiotic composition of active carbon and preparation method thereof |
| KR102468230B1 (en) * | 2022-08-19 | 2022-11-18 | 주식회사 레이어스코스메틱 | A fermentation method of raw material using lactobacillus strain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103989170B (en) | 2015-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109123295B (en) | Probiotic solid beverage and preparation method thereof | |
| CN105995976A (en) | Integrated enzyme powder having effects of reducing fat and losing weight and application thereof | |
| CN103989170B (en) | Solid granules capable of reducing blood fat and relaxing bowels and preparation method of solid granules | |
| KR20140057838A (en) | Fermented foods process and production method | |
| CN1911118B (en) | Kefir mushroom freeze-dried powder, production method and use thereof | |
| CN112999261B (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
| CN105029407A (en) | Medical formula food for inflammatory bowel disease | |
| CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
| CN104187611A (en) | Total nutrient formula food for gastrointestinal malabsorption | |
| CN106798252A (en) | A kind of natto prescription with coordinating intestines and stomach reducing blood lipid thrombus dissolving effect | |
| CN104839680A (en) | Medical formula food for people with cardiovascular diseases | |
| CN105018408A (en) | Method for promoting growth of probiotics by adding rutin in culture medium | |
| CN109288063A (en) | A kind of multi-joint Cernevit-12 and preparation method thereof being proliferated beneficial bacteria of intestinal tract | |
| CN108685006A (en) | A kind of 3 solid beverage of omega | |
| CN110179032A (en) | A kind of Noni fruit composite enzyme and its production method | |
| CN102742653B (en) | Brain-strengthening and nerve soothing probiotic goat milk tablet and preparation method of brain-strengthening and nerve soothing probiotic goat milk tablet | |
| CN105029393A (en) | Medical formula food for children | |
| CN105030950A (en) | Hyperlipidemia preventing and treating microecological preparation and preparation method and application thereof | |
| CN104686682A (en) | Probiotic fermentation milk drink with bowel relaxing and blood fat reduction assisting functions and making method thereof | |
| CN104146254A (en) | Full-nutrition formulated food for hypertension | |
| CN110771766A (en) | Probiotic health-care beverage for treating child intestinal colic and diarrhea and repairing intestinal tract | |
| CN104839676A (en) | Medical formula food for people with gastrointestinal tract absorption obstacle | |
| CN104187721A (en) | Total nutrient formula food for cardiovascular diseases | |
| CN107660670A (en) | Bitter buckwheat probiotics drink and preparation method thereof | |
| CN102754695A (en) | Burdock probiotics goat milk slices and method for preparing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190923 Address after: 473300 West Ring Road, Panhe Street Office, Sheqi County, Nanyang City, Henan Province (south of Hongda Road) Patentee after: Nanyang Fenghuang Hi-Tech Food Science Park Co., Ltd. Address before: Nanyang City, Henan province 473300 Sheqi County Rural Township West Ring Road West (HTC Road South) Patentee before: Nanyang Zhong Dao ecological agriculture Co., Ltd |
|
| TR01 | Transfer of patent right |